• Reported GAAP EPS of -$0.83 down -25.76% YoY • Reported revenue of $18.27M up 29.47% YoY • Kura Oncology expects its $580.8M in cash, plus $180M in anticipated collaboration payments, to fund the ziftomenib AML program through topline KOMET-017 Phase 3 results anticipated in 2028.
Bullish
Kura Oncology's KOMZIFTI generated $5.8M in net product revenue with strong early launch momentum and over 93% payer coverage, while ziftomenib pipeline advancements promise multiple 2026 data readouts.
Bearish
Kura Oncology experienced an increased net loss of $73.3M in Q1 2026, alongside rising R&D and SG&A expenses, while KOMZIFTI carries significant safety risks including fatal differentiation syndrome and QTc prolongation.